Dose effects of continuous vinblastine chemotherapy on mammalian angiogenesis mediated by VEGF-A

Acta Oncologica

Volumn 47, Issue 2, 2008, Pages 293-300

  Albertsson, Per ^a   Lennernäs, Bo ^a   Norrby, Klas ^a,b  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

VASCULOTROPIN A; VINBLASTINE SULFATE;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG FORMULATION; MESENTERY; MODEL; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; MESENTERY; NEOVASCULARIZATION, PATHOLOGIC; RATS; RATS, SPRAGUE-DAWLEY; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VINBLASTINE; WEIGHT GAIN;

EID: 38349154173     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.1080/02841860701558781     Document Type: Article

References (46)

1. Browder T, Butterfield CE, Kraling BM, Shi B, Marshall B, O'Reilly MS, et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000;60:1878-86.
2. Hanahan D, Bergers G, Bergsland E. Less is more, regularly: Metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest 2000;105:1045-7.
3. Albertsson P, Lennernas B, Norrby K. On metronomic chemotherapy: Modulation of angiogenesis mediated by VEGF-A. Acta Oncol 2006;45:144-55.
4. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
5. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995;1:27-31.
6. Klement G, Huang P, Mayer B, Green SK, Man S, Bohlen P, et al. Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts. Clin Cancer Res 2002;8:221-32.
7. Klement G, Baruchel S, Rak J, Man S, Clark K, Hicklin DJ, et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 2000;105:R15-24.
8. Gately S, Kerbel R. Antiangiogenic scheduling of lower dose cancer chemotherapy. Cancer J 2001;7:427-36.
9. Pasquier E, Honore S, Braguer D. Microtubule-targeting agents in angiogenesis: Where do we stand? Drug Resist Update 2006;9:74-86.
10. Baguley BC, Holdaway KM, Thomsen LL, Zhuang L, Zwi LJ. Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicine: Evidence for a vascular mechanism. Eur J Cancer 1991;27:482-7.
11. Hill SA, Lonergan SJ, Denekamp J, Chaplin DJ. Vinca alkaloids: Anti-vascular effects in a murine tumour. Eur J Cancer 1993;29A:1320-4.
12. Vacca A, Iurlaro M, Ribatti D, Minischetti M, Nico B, Ria R, et al. Antiangiogenesis is produced by nontoxic doses of vinblastine. Blood 1999;94:4143-55.
13. Bergers G, Hanahan D. Combining antiangiogenic agents with metronomic chemotherapy enhances efficacy against late-stage pancreatic islet carcinomas in mice. Cold Spring Harb Symp Quant Biol 2002;67:293-300.
14. Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 2004;4:423-36.
15. Kerbel RS. Antiangiogenic therapy: A universal chemosensitization strategy for cancer? Science 2006;312(5777):1171-5.
16. Mancuso P, Colleoni M, Calleri A, Orlando L, Maisonneuve P, Pruneri G, et al. Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy. Blood 2006;108:452-9.
17. Stempak D, Seely D, Baruchel S. Metronomic dosing of chemotherapy: Applications in pediatric oncology. Cancer Invest 2006;24:432-43.
18. Hlatky L, Hahnfeldt P, Folkman J. Clinical application of antiangiogenic therapy: Microvessel density, what it does and doesn't tell us. J Natl Cancer Inst 2002;94:883-93.
19. Kerbel RS, Klement G, Pritchard KI, Kamen B. Continuous low-dose anti-angiogenic/ metronomic chemotherapy: From the research laboratory into the oncology clinic. Ann Oncol 2002;13:12-5.
20. Lennernas B, Albertsson P, Lennernas H, Norrby K. Chemotherapy and antiangiogenesis - drug-specific, dose-related effects. Acta Oncol 2003;42:294-303.
21. StCroix B, Rago C, Velculescu V, Traverso G, Romans KE, Montgomery E, et al. Genes expressed in human tumor endothelium. Science 2000;289(5482):1197-202.
22. Hida K, Hida Y, Amin DN, Flint AF, Panigrahy D, Morton CC, et al. Tumor-associated endothelial cells with cytogenetic abnormalities. Cancer Res 2004;64:8249-55.
23. Jain RK, Munn LL, Fukumura D. Dissecting tumour pathophysiology using intravital microscopy. Nat Rev Cancer 2002;2:266-76.
24. Norrby K. In vivo models of angiogenesis. J Cell Mol Med 2006;10:588-612.
25. Folkman J. Angiogenesis: An organizing principle for drug discovery? Nat Rev Drug Discov 2007;6:273-86.
26. Norrby K. Microvascular density in terms of number and length of microvessel segments per unit tissue volume in mammalian angiogenesis. Microvasc Res 1998;55:43-53.
27. Norrby K. Angiogenesis: New aspects relating to its initiation and control. Apmis 1997;105:417-37.
28. Naslund I, Norrby K. NO and de novo mammalian angiogenesis: Further evidence that NO inhibits bFGF-induced angiogenesis while not influencing VEGF165-induced angiogenesis. Apmis 2000;108:29-37.
29. Lennernas B, Albertsson P, Damber JE, Norrby K. Antiangiogenic effect of metronomic paclitaxel treatment in prostate cancer and non-tumor tissue in the same animals: A quantitative study. Apmis 2004;112:201-9.
30. Albertsson P, Lennernas B, Norrby K. Chemotherapy and antiangiogenesis: Drug-specific effects on microvessel sprouting. Apmis 2003;111:995-1003.
31. United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) Guidelines for the Welfare of Animals in Experimental Neoplasia. 2nd ed. Br J Cancer 1998;77:1-10.
32. Norrby K. Vascular endothelial growth factor and de novo mammalian angiogenesis. Microvasc Res 1996;51:153-63.
33. Freireich EJ, Gehan EA, Rall DP, Schmidt LH, Skipper HE. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother Rep 1966;50:219-44.
34. Davidson IW, Parker JC, Beliles RP. Biological basis for extrapolation across mammalian species. Regul Toxicol Pharmacol 1986;6:211-37.
35. Dixon RL. Problems in extrapolating toxicity data for laboratory animals to man. Environ Health Perspect 1976;13:43-50.
36. Rahmani R, Zhou XJ. Pharmacokinetics and metabolism of vinca alkaloids. Cancer Surv 1993;17:269-81.
37. Zhou XJ, Martin M, Placidi M, Cano JP, Rahmani R. In vivo and in vitro pharmacokinetics and metabolism of vincaalkaloids in rat. II. Vinblastine and vincristine. Eur J Drug Metab Pharmacokinet 1990;15:323-32.
38. Norrby K. Basic fibroblast growth factor and de novo mammalian angiogenesis. Microvasc Res 1994;48:96-113.
39. Norrby K, Bergstrom S, Druvefors P. Hyperplasia and growth of the true mesentery in the diabetic rat. Acta Pathol Microbiol Immunol Scand [A] 1983;91:195-202.
40. Norrby K, Franzen L. A tissue model for the study of cell proliferation in vitro. In Vitro 1980;16:31-7.
41. Norrby K, Mattsby-Baltzer I, Innocenti M, Tuneberg S. Orally administered bovine lactoferrin systemically inhibits VEGF(165)-mediated angiogenesis in the rat. Int J Cancer 2001;91:236-40.
42. Hayot C, Farinelle S, De Decker R, Decaestecker C, Darro F, Kiss R, et al. In vitro pharmacological characterizations of the anti-angiogenic and anti-tumor cell migration properties mediated by microtubule-affecting drugs, with special emphasis on the organization of the actin cytoskeleton. Int J Oncol 2002;21:417-25.
43. Young SD, Whissell M, Noble JC, Cano PO, Lopez PG, Germond CJ. Phase II clinical trial results involving treatment with low-dose daily oral cyclophosphamide, weekly vinblastine, and rofecoxib in patients with advanced solid tumors. Clin Cancer Res 2006;12:3092-8.
44. Emmenegger U, Man S, Shaked Y, Francia G, Wong JW, Hicklin DJ, et al. A comparative analysis of low-dose metronomic cyclophosphamide reveals absent or low-grade toxicity on tissues highly sensitive to the toxic effects of maximum tolerated dose regimens. Cancer Res 2004;64:3994-4000.
45. Shaked Y, Emmenegger U, Man S, Cervi D, Bertolini F, Ben-David Y, et al. Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity. Blood 2005;106:3058-61.
46. Poiley SM. Growth tables for 66 strains and stocks of laboratory animals. Lab Anim Sci 1972;22:758-79.